Clinical Efficacy of the Product in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP) Subjects

Inclusion Criteria: * Female and male subjects aged between 18 - 50 years old. * Subject of Fitzpatrick phototype III-VI. * Subject must be willing and be able to comply with the study schedule, procedures, and restrictions. * Subjects with moderate to severe scores (4-8) on mean darkness intensity. * Subjects with moderate to severe PIHP due to acne (score PAPHI\>10). * Subjects with mild acne (GEA 2), * Subjects having ≤ 4 inflammatory lesions total, * Subjects showing understanding of the study procedures, restrictions, willingness to participate as evidenced by voluntary written informed consent. Exclusion criteria * Pregnant or intending to become pregnant during the study or breastfeeding or in menopause. * Subjects under any hormonal therapy, such as contraceptive pills or androgen agonist/antagonist medications, within the last 3 months before Visit 1 or planning to start any therapy during the study. * Subject with cutaneous pathology on the studied zone other than acne (eczema etc.). * Use of topical or systemic treatment during the previous weeks liable to interfere with the assessment of the acceptability and efficacy of the studied products (according to the investigator's appreciation). * Moderate to severe acne (GEA \>2). * Systemic treatment of retinoids during the six previous months of the study. * Under retinoid treatment within the last 6 months, including Over. The Counter (OTC) and all derivates of retinoids (e.g., retinol, retinal, retinaldehyde, retinol esters, etc.). * Under any acne medication (including oral medication/laser treatment) within the last 6 months. * Subjects treated for PIHP within the past 3 months with either a cosmetic product or a drug. * Subject with make-up products on the day of the visit at the center. * Cosmetic product for non-comedogenicity within the last 2 weeks. * History of skin cancer. * History of abnormal response to sun. * Presence of recent suntan (according to Investigator opinion) or photo-test marks. * History of allergy, hypersensitivity, or any serious reaction to any cosmetic product. * Any concomitant medical condition that may interfere with the study conduct in the opinion of the investigator. * Having used within the month before inclusion any systemic medication for more than 5 consecutive days (e.g., steroidal, and non-steroidal anti-inflammatory drugs, corticoids, insulin, antihistamines, antihypertensive, antibiotics -e.g., quinolone, tetracycline, thiazides, fluoroquinolones-). * Any subject who, in the judgment of the Investigator, should not participate in the study. * Subject who cannot be contacted by telephone in case of emergency. * Subject having participated within the 14 days before inclusion or currently participating in another clinical study.